ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

CGEM Cullinan Therapeutics Inc

27.89
-0.21 (-0.75%)
2024年5月3日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Cullinan Therapeutics Inc CGEM NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.21 -0.75% 27.89 08:29:53
始値 安値 高値 終値 前日終値
28.22 26.73 28.22 27.58 28.10
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/2920:00GLOBECullinan Therapeutics Announces Appointment of Mary Kay..
2024/4/2423:09GLOBECullinan Therapeutics to Present Clinical Data from Phase 1..
2024/4/1620:00GLOBECullinan Therapeutics Announces Strategic Expansion into..
2024/4/1619:59GLOBECullinan Therapeutics Announces Oversubscribed $280 million..
2024/3/1420:00GLOBECullinan Oncology Provides Corporate Update and Reports..
2024/3/0121:00GLOBECullinan Oncology Announces U.S. FDA Clearance of..
2024/2/2722:00GLOBECullinan Oncology to Participate in Upcoming Investor..
2024/2/2407:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2407:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2407:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1511:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2024/2/0311:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0206:43EDGAR2Form 144 - Report of proposed sale of securities
2024/1/3109:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/3006:27EDGAR2Form 144 - Report of proposed sale of securities
2024/1/2507:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/2306:18EDGAR2Form 144 - Report of proposed sale of securities
2024/1/0906:15EDGAR2Form 8-K/A - Current report: [Amend]
2024/1/0823:12EDGAR2Form 8-K - Current report
2023/12/2307:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2307:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2307:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2307:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2108:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2108:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2108:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2108:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1906:53GLOBECullinan Oncology to Present at the 42nd Annual J.P. Morgan..
2023/12/1506:30GLOBECullinan Oncology Announces First Patient Dosed in Phase 1..
2023/12/1410:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1410:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/0821:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0821:10EDGAR2Form 8-K - Current report
2023/11/0821:00GLOBECullinan Oncology Provides Corporate Update and Reports..
2023/11/0401:01GLOBECullinan Oncology to Present Data Demonstrating Progress..
2023/10/3021:00GLOBECullinan Oncology to Participate in Upcoming Investor..
2023/9/0621:00GLOBECullinan Oncology to Participate in Upcoming Investor..
2023/8/1020:44EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/1020:07EDGAR2Form 8-K - Current report
2023/8/1020:00GLOBECullinan Oncology Provides Corporate Update and Reports..
2023/8/0920:00GLOBECullinan Oncology Announces First Patient Dosed in Phase 1..
2023/8/0405:15PRNUSREZILIENT3 Global First-Line Trial of Zipalertinib Launched..
2023/7/3121:00GLOBECullinan Oncology to Participate in Upcoming Investor..
2023/7/0610:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/5/2606:00GLOBECullinan Oncology to Present First Monotherapy Clinical Data..
2023/5/1205:01GLOBECullinan Oncology Provides Corporate Update and Reports..

最近閲覧した銘柄

Delayed Upgrade Clock